Top ▲
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | - | 375 | 5q31.3 | CD14 | CD14 molecule | |
| Previous and Unofficial Names |
| myeloid cell-specific leucine-rich glycoprotein |
| Database Links |
|
| Alphafold | P08571 (Hs) |
| ChEMBL Target | CHEMBL2384897 (Hs) |
| Ensembl Gene | ENSG00000170458 (Hs) |
| Entrez Gene | 929 (Hs) |
| Human Protein Atlas | ENSG00000170458 (Hs) |
| KEGG Gene | hsa:929 (Hs) |
| OMIM | 58120 (Hs) |
| Pharos | P08571 (Hs) |
| RefSeq Nucleotide | NM_000591 (Hs) |
| RefSeq Protein | NP_000582 (Hs) |
| UniProtKB | P08571 (Hs) |
| Wikipedia | CD14 (Hs) |
Download all structure-activity data for this target as a CSV file 
| Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Antibody Comments | |||||||||||||||||||||||||||||||||||||||||||||||||||
| The use of anti-CD14 monoclonal antibodies to treat viral infection is claimed in Implicit Bioscience's patent WO2018165720A1. Their clinical candidate IC14 which was derived from murine clone 28C5, is claimed in this patent. | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| Because of its key role in amplifying the immune response, CD14 was targeted for pharmacological modulation. Implicit Bioscience developed a first-in-class anti-CD14 monoclonal antbody (atibuclimab; IC14) as a clinical lead [6-7]. Atibuclimab was evaluated for immunomodulatory potential in ALS/MND and was explored for efficacy against acute respiratory distress syndrome (ARDS) and sepsis [1,4,7]. In April 2020, in response to the COVID-19 pandemic, Implicit initiated a clinical trial (NCT04346277) to investigate the potential of CD14 modulation as a mechanism to mitigate against cytokine storm and ARDS in patients with this potentially deadly disease. Atibuclimab was predicted to prevent CD14 from participating in the recognition of PAMPs and DAMPs that are generated during SARS-CoV-2 infection. A search of ClinicalTrials.gov in March 2024 revealed that the majority of atibuclimab studies had been terminated or withdrawn. |
| Cell Type Associations | ||||||
|
| Tissue Distribution
|
||||||||
|
| Physiological Consequences of Altering Gene Expression
|
||||||||||
|
| General Comments |
| CD14 acts as a scavenger receptor for bacterial lipopolysaccharide. It is present as a phosphatidylinositol phospholipid anchored membrane protein and in circulating soluble form [5]. CD14 recognises LPS bound to lipopolysaccharide-binding protein (LBP; HGNC 6517) and delivers it to the LY96/TLR4 complex, to amplify the inflammatory response to pathogens and to DAMPS. Engagement of the TLR pathway results in signals that prompt leukocyte recruitment, NF-κB activation and cytokine secretion. |
1. Axtelle T, Pribble J. (2001) IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J Endotoxin Res, 7 (4): 310-4. [PMID:11717588]
2. Haziot A, Ferrero E, Köntgen F, Hijiya N, Yamamoto S, Silver J, Stewart CL, Goyert SM. (1996) Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity, 4 (4): 407-14. [PMID:8612135]
3. Jersmann HP. (2005) Time to abandon dogma: CD14 is expressed by non-myeloid lineage cells. Immunol Cell Biol, 83 (5): 462-7. [PMID:16174094]
4. Reinhart K, Glück T, Ligtenberg J, Tschaikowsky K, Bruining A, Bakker J, Opal S, Moldawer LL, Axtelle T, Turner T et al.. (2004) CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit Care Med, 32 (5): 1100-8. [PMID:15190957]
5. Simmons DL, Tan S, Tenen DG, Nicholson-Weller A, Seed B. (1989) Monocyte antigen CD14 is a phospholipid anchored membrane protein. Blood, 73 (1): 284-9. [PMID:2462937]
6. Spek CA, Verbon A, Aberson H, Pribble JP, McElgunn CJ, Turner T, Axtelle T, Schouten J, Van Der Poll T, Reitsma PH. (2003) Treatment with an anti-CD14 monoclonal antibody delays and inhibits lipopolysaccharide-induced gene expression in humans in vivo. J Clin Immunol, 23 (2): 132-40. [PMID:12757265]
7. Verbon A, Dekkers PE, ten Hove T, Hack CE, Pribble JP, Turner T, Souza S, Axtelle T, Hoek FJ, van Deventer SJ et al.. (2001) IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol, 166 (5): 3599-605. [PMID:11207321]
CD molecules: CD14 molecule. Last modified on 19/03/2024. Accessed on 25/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3126.
target has curated data in GtoImmuPdb
